AD/PD™ 2019, Lisbon - AD/PD™ in the News

AD/PD in the News

Read about the AD/PD 2019 Conference which took place in Lisbon, Portugal on 26-31 March 2019.


Cure in Mind, Cure in Sight – Bridging Eye and Brain Research

BrightFocus Convenes and Leads the Pre-Conference Workshop
"Common Features of Neurodegenerative Diseases:  Exploring the Brain-Eye Connection and Beyond"

"The attendance at this year’s workshop, and the caliber of faculty and participants, all point to the importance of the topic and growing interest in  exploring common connections between eye and brain diseases.  In a one-day workshop of this type, collaborations are sparked and valuable knowledge is shared."


ALZFORUM Conference Coverage Series

"Held in romantically beautiful Lisbon, this AD/PD was the biggest thus far, drawing 3,982 attendees from 73 countries"


At AD/PD Conference, New Alzheimer’s Genes Reinforce Known Pathways

"After years of grunt work on next-gen sequencing and expression analysis, geneticists are finally reaping results. The new genes underscore the role of known pathways and cell types in disease."


Expression, Expression, Expression—Time to Get on Board with eQTLs

"A tool of modern genetics, expression studies link GWAS hits to specific cell types, providing clues to pathogenesis. Microglia come up again and again."


APP Upp: Mutation Nixes Six Amino Acids from Aβ, Spurs Aggregation

"Presented at AD/PD, the discovery by scientists in Uppsala is the first APP deletion found to cause Alzheimer’s disease. The same group found the Swedish and Arctic APP mutations."


Parsing How Alzheimer’s Genetic Risk Works Through Microglia

"Scientists at AD/PD 2019 see a Goldilocks of microglial activation: Both too little and too much is bad in an injured brain. How could a therapy make it just right?"


Could CD33 Be the Microglial Target for Stimulating Phagocytosis?

"Inhibiting the receptor activates microglia to mop up debris, making CD33 an attractive therapeutic target."


Could Greasing the Wheels of Lipid Processing Treat Alzheimer’s?

"Speakers at AD/PD 2019 reported that AD risk factors mess up lipid metabolism in glial cells. In cellular models, speeding the clearance of fats lessened pathology."


Chimeric Mice: Can They Model Human Microglial Responses?

"By slipping human microglia inside the mouse brain, researchers hope to better monitor their response to pathologies, such as Aβ."


Spitting, Sniffing: Is This How We Will Dx Parkinson’s?

"Scientists are probing saliva and skin secretions for telltale signs of Parkinson’s disease. Their prize? A diagnostic test at the pre-motor stage."


ARIAS: Zooming in On Eye-based Biomarkers for Alzheimer’s

"Scientists know that the retina changes in people with preclinical AD; alas, there is neither consensus nor convergence in the field of retinal imaging. An upcoming initiative aims to determine which measures are most robust."


On The Docket at AD/PD: The Many Crimes of ApoE4

"Microglia cleanup, mitophagy, axonal plasticity, blood-brain barrier. A renewed focus on ApoE4 is revealing new ways in which this isoform renders the brain vulnerable to Alzheimer’s."


Off-Balance Endocytosis Lays Groundwork for Disease

"By aging cultured neurons and manipulating them to stimulate endocytosis or interfere with vesicle release, researchers can bring about characteristics of Alzheimer’s—without adding APP or Aβ."


Antibodies Against Microglial Receptors TREM2 and CD33 Head to Trials

"As data increasingly blame the microglia response as a driving force in Alzheimer’s disease, researchers are investigating whether tempering these cells will aid cognition."


Do Immune Cells Promote the Spread of α-Synuclein Pathology?

"At AD/PD 2019, scientists implicated both peripheral and central innate immunity in promoting propagation."


Forget Fibrils: Lewy Pathology Is More Lipid Than Protein

"An electron microscopy study reveals a jumbled mess of membrane chunks and malfunctioning organelles, bound together by phosphorylated or truncated α-synuclein."


Keep Your Enthusiasm? Scientists Process Brutal Trial Data

"“We are learning” was the tenor of debate about the latest round of setbacks for anti-amyloid trials in symptomatic Alzheimer’s disease at a recent conference in Lisbon."


BACE Inhibitors: Postmortem on One, Live Updates on Two

"Lanabecestat, elenbecestat, and umibecestat all showed data at the AD/PD conference in Lisbon. Learn what definitely doesn’t work and what might yet."


Human Microglia Make Themselves at Home in Mouse Brain

"Analysis of a chimeric mouse shows that the cells express the same genes they do in the human brain, survey their environment, and respond to injuries and amyloid."


AD/PD™ 2017


Read about the AD/PD™ 2017 Conference which took place in Vienna, Austria on 29 March-2 April 2017.

Cure Alzheimer's Fund Co-Sponsors 13th International Conference on Alzheimer's and Parkinson's Diseases

Advancements in Alzheimer's in a Dish are highlighted

"More than 3400 scientists from around the world attended the conference, which provided a platform to share the latest research, developments, and medical breakthroughs on Alzheimer's, Parkinson's, and other neurodegenerative diseases."



ALZFORUM Conference Coverage Series


"The meeting jammed science into five parallel sessions, with 545 talks running from early morning till late evening and some 1,200 posters vying for attention." 


"This five day conference saw over 3000 clinicians, researchers industry specialists from around the globe discuss recent advances in the field, including reports on the latest drug trails, new avenues for treatment and patient perspectives."


"There was clearly an expanse of common ground between them in terms of the research techniques being developed and the molecular pathways and cellular mechanisms being explored. It was encouraging to see researchers working on one condition learning from the successes and failures of those working in a related disease area."


"ProMIS Neurosciences, a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announces results of its recent therapeutic developments presented at the 13th International Conference on Alzheimer's (AD) and Parkinson's diseases held in Vienna, Austria, from March 29 to April 2nd. This year's conference was devoted to mechanisms, clinical strategies and promising treatments of neurodegenerative diseases."


"Long-term use of the diabetes medication metformin may increase the risk for neurodegenerative disease in patients with type 2 diabetes mellitus (T2DM), new research suggests. The results were presented here at AD/PD 2017: The 13th International Conference on Alzheimer's and Parkinson's Diseases by Yi-Chun Kuan, MD, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan."


"Education, as a proxy for cognitive reserve, appears neuroprotective during early stages of the aging process but becomes less beneficial in later stages — and can even have a negative effect in patients with late amnestic mild cognitive impairment (aMCI) or mild Alzheimer's dementia (AD), new research suggests.However, those with late aMCI or mild AD had negative correlations in several brain areas, "showing a more disrupted resting-state functional network," lead author, Yeshin Kim, MD, Samsung Medical Center, Seoul, Republic of Korea, told attendees here at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD) 2017."


"Although past studies have shown that social relationships are important during the aging process, new research suggests that cognitive benefits may differ between types of social roles — at least in older women. Burn presented the findings here at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD) 2017."


"Decreased near-vision function in older patients may increase the risk for later dementia, new research suggests. "The main message is that clinicians need to be careful of eye vision and realize its importance for these patients," lead author, Virginie Nael. She presented the findings here at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD) 2017."


"Patients with enlarged brain ventricles and clinically suspected idiopathic normal-pressure hydrocephalus (iNPH) may be at increased risk for dementia, new research suggests... She presented the findings at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD) 2017."


"Levels of iron in specific areas of the brain may help clinicians to differentiate a diagnosis of Parkinson's disease (PD) from nondegenerative tremor syndromes (ND-TS), suggests new imaging research. Still, lead author Sebastian Franthal, MD, Department of Neurology, Medical University of Graz, Austria, told attendees here at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD) 2017 that the overall difference in brain-iron "is a novel finding."


"Throughout the Alzheimer's and Parkinson's Disease (AD/PD) Congress 2017, there were a number of recurring topics providing insight into the current and future focus of Alzheimer's disease (AD) research and development (R&D) efforts."


"During a forum discussion session at the Alzheimer's & Parkinson's Disease (AD/PD) Congress 2017, the panel of corporate executives from the leading players in Alzheimer's disease (AD) research, including Eli Lilly, Roche, Janssen, Eisai, and Biogen, discussed the lessons learned from the past failures and strategies for achieving success in the late stages of AD drug development. In response to some difficult questions from the audience, the panel highlighted targeting the wrong patient population, lack of biomarkers, and insufficient understanding of drugs’ mechanisms of action as some of the key contributors to the recent failures. They emphasized that companies must have clear strategies from early trial phases to tackle these challenges and to succeed in AD drug development."